Century Therapeutics (NASDAQ:IPSC) Stock Rating Lowered by Wall Street Zen

Century Therapeutics (NASDAQ:IPSC) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Century Therapeutics in a research report on Tuesday, September 29th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Century Therapeutics presently has an average rating of “Hold” and an average price target of $4.75.

Century Therapeutics Stock Performance

Shares of IPSC opened at $1.49 on Friday. The stock has a 50 day moving average price of $1.74 and a two-hundred day moving average price of $2.09. Century Therapeutics has a 52 week low of $0.43 and a 52 week high of $3.04. The firm has a market capitalization of $269.61 million, a P/E ratio of -1.60 and a beta of 1.78.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). On average, equities analysts forecast that Century Therapeutics will post -0.51 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Versant Venture Management LLC acquired a new stake in shares of Century Therapeutics in the 1st quarter worth about $27,495,000. Commodore Capital LP acquired a new position in shares of Century Therapeutics during the 1st quarter worth approximately $19,652,000. BlackRock Inc. purchased a new position in Century Therapeutics in the second quarter valued at approximately $19,825,000. Seven Fleet Capital Management LP acquired a new position in Century Therapeutics in the 1st quarter valued at about $9,826,000. Finally, Trails Edge Capital Partners LP acquired a new stake in shares of Century Therapeutics in the 2nd quarter valued at about $10,130,674. Institutional investors own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc is a biotechnology company focused on developing allogeneic, or “off-the-shelf,” cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create immune-effector cells, including natural killer (NK) cells and T cells, that can be engineered to recognize and attack tumor cells.

Century’s pipeline has included product candidates designed for hematologic malignancies and solid tumors. Its programs incorporate technologies intended to improve the persistence, activity, and scalability of engineered immune cells, with development efforts involving targets such as CD19 and other tumor-associated antigens.